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Abstract
Background: Differences in clinical outcomes following a temporary interruption of
warfarin or a direct oral anticoagulant (DOAC) for a surgical procedure are not well
described. Differences in patient characteristics from practice-based cohorts have
not typically been accounted for in prior analyses.
Aim: To describe risk-adjusted differences in postoperative outcomes following an
interruption of warfarin vs DOACs.
Methods: Patients receiving care at six anticoagulation clinics participating in the
Michigan Anticoagulation Quality Improvement Initiative were included if they had
at least one oral anticoagulant interruption for a procedure. Inverse probability of
treatment weighting (IPTW) was used to balance baseline differences between the
warfarin cohort and DOAC cohort. Bleeding and thromboembolic events within
30 days following the procedure were compared between the IPTW cohorts using
the Poisson distribution test.
Results: A total of 525 DOAC patients were matched with 1323 warfarin patients,
of which 923 were nonbridged warfarin patients and 400 were bridged warfarin patients. The occurrence of postoperative minor bleeding (10.8% vs. 4.7%, p < .001),
major bleeding (2.9% vs. 1.1%, p = .01) and clinically relevant nonmajor bleeding
(CRNMB) (6.5% vs. 3.0%, p = .002) was greater in the DOAC cohort compared with
the nonbridged warfarin cohort. The rates of postoperative bleeding outcomes were
similar between the DOAC and the bridged warfarin cohorts.
Conclusion: Perioperative interruption of DOACs, compared with warfarin without
bridging, is associated with a higher incidence of 30-day minor bleeds, major bleeds,
and CRNMBs. Further research investigating the perioperative outcomes of these
two classes of anticoagulants is warranted.
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1 | I NTRO D U C TI O N
The direct oral anticoagulants (DOACs), which include apixaban, dabigatran, rivaroxaban, and edoxaban, are now first-line therapy for
treatment of venous thromboembolism (VTE) and stroke prevention
in atrial fibrillation (AF). Many patients taking chronic anticoagulant
therapy will require temporary interruption for a surgical procedure.1 Management of the anticoagulant in the perioperative period
can be complicated because the pharmacokinetic properties of each
agent differ, most significantly as compared with warfarin.
Because of its long half-life, warfarin is often interrupted several
days before the procedure. For patients with a high risk of throm-

Essentials
• Few studies adjust for cofounders in ‘direct oral anticoagulants (DOAC)’ and warfarin cohorts.
• Inverse probability weighting used to balance covariates
between our DOAC and warfarin cohorts.
• No difference in postoperative adverse events between
DOAC cohort vs bridged warfarin cohort.
• DOAC cohort associated with higher rates of bleeding/
thrombosis vs non-bridged warfarin cohort.

botic complications, “bridging” therapy with low molecular weight
heparin or other short-acting parenteral anticoagulants are frequently used while the anticoagulant activity of warfarin wanes or

approval has been obtained at each site and the coordinating center

returns to therapeutic range. This practice, however, is associated

(University of Michigan).

with higher risk of bleeding compared with those in whom bridging
therapy was not initiated. 2–4 In contrast to warfarin, DOACs have
both a short half-life and rapid onset of action, which make them

2.1 | Patient selection

ideal for perioperative use and removes the necessity of bridging
anticoagulation.5,6 Prior studies have compared postoperative

Patients who had a temporary interruption of DOAC or warfarin

outcomes of patients following the perioperative interruption of

therapy for an elective surgical procedure were included if they had

DOACs vs. warfarin and found no major differences in postopera-

follow-up for at least 3 months after the procedure. Patients with in-

tive rates of major bleeding or thromboembolic events.7–10 However,

dications for anticoagulant use other than AF or VTE were excluded.

because these were post hoc analyses of clinical trials, the patient
samples include a more selective population that is commonly seen
in routine clinical practice. Therefore, we aimed to compare 30-day

2.2 | Data collection

postoperative bleeding and thromboembolic events associated with
DOAC versus warfarin management in the perioperative period in a

Baseline patient information, including demographics, medications,

practice-based cohort of patients.

and comorbidities were abstracted from patient charts at the time
of anticoagulation initiation. Information about medication changes,
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M ATE R I A L S A N D M E TH O DS

new comorbidities, procedures, and bleeding or thrombotic events
were abstracted for each patient interaction with the anticoagulation management service for warfarin-treated patients and at regular

The Michigan Anticoagulation Quality Improvement Initiative

6-month follow-up intervals for DOAC-treated patients. Procedural

(MAQI2) is a Blue Cross Blue Shield of Michigan/Blue Care Network-

data abstracted from the medical record included the date of proce-

funded multicenter collaborative of anticoagulation management

dure, anticoagulation interruption and restart dates, whether or not

2

services in the state of Michigan. MAQI was formed in 2008 with

heparin bridging was used, and the type of procedure. The proce-

the goal of improving patient safety and outcomes by collecting

dures were categorized into having low or high bleed risk based on

and comparing patient clinical data, identifying best practices, and

categories from the BRIDGE trial.3

conducting quality improvement initiatives. Currently, there are six
hospitals in Michigan participating in the program. Patients initiated
on either a DOAC or warfarin are randomly selected for entry into

2.3 | Outcomes

the MAQI2 database and followed longitudinally so long as they remain on therapy and are managed at the participating health system.

The primary outcomes of our study were 30-day postoperative

All data abstractors undergo training, and each center undergoes

thromboembolic or bleeding events. Thromboembolic events in-

regular audits to ensure high-quality data collection and agreement

cluded the composite of transient ischemic attacks, ischemic stroke,

with predefined data element definitions. More information about

and VTE. Bleeding events were classified into minor bleeds, major

MAQI2 has been previously described.11 Institutional review board

bleeds, and clinically relevant nonmajor bleeds (CRNMB). Criteria

|
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for major and CRNMBs were based on International Society on
12,13

Thrombosis and Haemostasis (ISTH) definitions.

3

(20.7% vs. 11.2%, p < .001), had a lower modified HAS-BLED score
(2.58 vs. 3.01, p < .001), and had a lower rate of high bleed risk procedures (30.1% vs. 43.0%, p < .001), had a higher rate of low bleed

2.4 | Statistical analysis

risk procedures (69.3% vs. 54.1%, p < .001), were taking their anticoagulant for more days before the procedure (480 vs. 243, p < .001),
stopped taking their anticoagulant for more days before the pro-

Inverse probability of treatment weighting (IPTW) was used to

cedure (5 vs. 3, p < .001), and had a lower procedure to restart in-

compare the DOAC and warfarin treatment groups. This statistical

terval (0 vs. 1, p = .002). No other significant differences in patient

method assigns a weight to each patient based on their propensity

characteristics or procedure bleed risk between the groups were

score, creating a pseudopopulation that allows us to better deter-

found (Table 1A). Thirty-nine bleeding events occurred in patients

mine the effects of the two treatments. The IPTW approach allows

taking apixaban 5 mg twice daily, and 33 occurred in patients taking

us to use the entirety of our cohort and maximize the inclusion of as

rivaroxaban 20 mg each day, which were the two dosages with the

many warfarin-treated and DOAC-treated patients as possible while

highest incidence of bleeding events among the DOAC cohort.

preserving exact matching for sex, anticoagulation indication, and
procedural bleeding risk. Other clinical variables were included in
the IPTW, and a standardized difference of less than 0.1 was con-

3.2 | Postoperative outcomes

sidered negligible (Appendix S1). Bleeding and thromboembolic risk
comparisons were adjusted for the average modified HAS-BLED

Among the 1323 warfarin patients and 525 DOAC patients in the

(excluding time in therapeutic range) scores.14,15 Following IPTW

treatment cohorts, 260 bleeding events and 12 thrombotic events

reweighting, multivariate logistic regression was performed to cal-

were reported. Compared with the nonbridged warfarin cohort, the

culate odds ratios that compared 30-day postoperative outcomes.

DOAC cohort had a significantly higher postoperative rate of both
minor bleeds (10.8% vs. 4.7%, p < .001), major bleeds (2.9% vs. 1.1%,

3
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3.1 | Study population

p = .01), and CRNMBs (6.5% vs. 3.0%, p = .002) (Table 1B). There
was no difference in the rate of thromboembolic events between
the nonbridged warfarin cohort and the DOAC cohort. Similarly,
there was no difference in any bleeding or thromboembolic events
between the bridged warfarin cohort and DOAC cohort.

Of a total of 14 168 warfarin and 3253 DOAC patients in the MAQI2
registry, 1323 (9%) warfarin-treated and 525 (16%) DOAC-treated
patients met inclusion/exclusion criteria for our study (Figure 1).

3.3 | IPTW outcomes

Following IPTW reweighting, differences between the two cohorts
were minimal (Appendix S1). Of the warfarin-treated patients, 400

Between the nonbridged warfarin cohort and the DOAC cohort,

of 1323 (30%) were bridged during the interruption. Compared

IPTW analysis indicates that DOAC use contributed most greatly

with the bridged warfarin cohort, the DOAC cohort was signifi-

to the differences in the rates of minor bleeds (OR 2.546, 95% CI

cantly older (71.0 years vs. 65.7 years, p < .001), had a higher con-

1.656–3.912), major bleeds (OR 3.712, 95% CI 1.605–8.584), and

comitant rate of hypertension (80.0% vs. 64.0%, p < .001), had more

CRNMBs (OR 2.928, 95% CI 1.718–4.991) (Figure 2).

cases of remote bleeding (6.5% vs. 3.5%, p = .04), were prescribed
less antiplatelets (26.5% vs. 41.8%, p < .001) and nonsteroidal anti-
inflammatory drugs (3.6% vs. 10.0%, p < .001), had more bleed-
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DISCUSSION

ing events before the procedure (17.5% vs. 11.2%, p = .007), had a
higher CHA 2DS2-VASc score (3.54 vs. 3.12, p = .001), had a lower

Among the 1323 warfarin patients and 525 DOAC patients who

rate of high bleed risk procedures (30.1% vs. 60.3%, p < .001), had a

underwent surgical procedure requiring perioperative interruption,

higher rate of low bleed risk procedures (69.3% vs. 36.5%, p < .001),

rates of minor bleeding, major bleeding, and bleeding requiring an

had a higher proportion of patients being treated for AF (70.7% vs.

emergency department visit were lower for patients treated with

35.3%, p < .001), were taking their anticoagulant for more days be-

warfarin and no bridging therapy than for DOAC-treated patients

fore the procedure (391 vs. 243, p < .001), and stopped taking their

following IPTW weighting. There were no differences in thrombo-

anticoagulant for more days before the procedure (5 vs. 3, p < .001).

embolic events between warfarin-treated patients without bridging

Compared with the nonbridged warfarin cohort, the DOAC cohort

and DOAC-treated patients, and no differences between warfarin-

was significantly younger (71.0 years vs. 72.4 years, p = .03), had

treated patients with bridging and DOAC-treated patients. IPTW

a lower rate of concomitant abnormal renal function (15.4% vs.

analysis indicates that DOAC use contributed most greatly to the

22.1%, p = .002), were prescribed fewer antiplatelets (26.5% vs.

differences in bleeding rates between the two cohorts.

43.1%, p < .001) and nonsteroidal anti-inflammatory drugs (3.6%

Given the large body of evidence associating bridging therapy

vs. 8.3%, p = .001), had more bleeding events before the procedure

with increased bleeding risk, it was unsurprising that the bridged

4
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F I G U R E 1 Matching procedure diagram
warfarin cohort had a numerically higher bleeding rate than to our

we also implemented IPTW before logistic regression to adjust for

Our bridged warfarin cohort saw sim-

confounding variables. 25 Their analysis also found that postopera-

ilar outcomes with our DOAC cohort with regard to bleeding and

tive rates of major bleeding were significantly higher in the warfarin

thromboembolic events. In contrast to warfarin, DOACs have both

cohort, which we did find in our analysis of our nonbridged war-

a short half-life and fast onset of action and thus do not require

farin cohort. However, there are various differences between the

unbridged warfarin cohort.

16,17

bridging.

2–4

This leads to a shortened time between the surgical

two studies that led to this shared finding. First, our study included

procedure and when a DOAC medication is stopped or restarted as

patients whose primary indication for anticoagulation was either AF

compared to warfarin. It is thus not unexpected that the addition of

or VTE, whereas the Shaw study focused on AF only, although our

a fast-acting bridging agent in our bridged warfarin cohort to result

study's IPTW analysis indicates that an indication of AF does not

in similar rates of bleeding compared to our DOAC cohort.

contribute to the differences in bleeding rates in the DOAC versus

DOAC-treated patients in our study experienced a postoperative

nonbridged warfarin cohorts (Figure 2). Additionally, we differenti-

major bleed rate of 2.9%, which is slightly higher (2.9% vs. 0.9%–

ated our warfarin patients into cohorts based on the use of bridging

1.85%) than the rates of the cohorts in PAUSE.18 However, our rate

low molecular weight heparin. Last, we used an IPTW statistical ap-

of minor bleeding was 10.8%, which is notably higher than the rates

proach, which may have resulted in different analysis of the variables

of 4.3%–5.7% of the cohorts of the PAUSE study. Two potential con-

and affected outcomes since IPTW sets our groups to be similar

tributing factors why our DOAC cohort had a higher rate of major

in our covariates before logistics regression. Further efforts are

bleeding are the higher rate of antiplatelet use19–21 (26.5% vs. 9.1%–

needed to reconcile the differences between these two important

14.7%) and a higher modified HAS-BLED score

22–24

(2.6 vs. 1.9).

studies of perioperative anticoagulation care.

Shaw and colleagues also performed a retrospective analysis of

The key strength of our study is the use of our IPTW statistical

warfarin and DOAC interruption for surgical procedures. In addi-

analysis, which is able to account for various potential confound-

tion to the multivariable logistic-regression model that they utilized,

ing variables in the warfarin and DOAC cohorts while maintaining

|
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TA B L E 1 (A) Patient characteristics and procedure bleed risk of warfarin-and DOAC-matched cohorts. (B) Thirty-day postoperative
outcomes
Warfarin (Bridged)
n = 400

Warfarin (Nonbridged)
n = 923

DOAC
n = 525

p-value Warfarin
Bridged vs. DOAC

p-value Warfarin
Nonbridged vs. DOAC

Age (mean ± SD)

65.7 ± 13.8

72.4 ± 11.7

71.0 ± 12.2

<.001

.03

Sex, n (%), male

198 (49.5)

493 (53.4)

262 (49.9)

.90

.20

HTN

256 (64)

717 (77.7)

420 (80.0)

<.001

.30

Abnormal renal
function

65 (16.3)

204 (22.1)

81 (15.4)

.73

.002

Abnormal hepatic/
liver function

12 (3)

37 (4)

25 (4.8)

.18

.50

TIA/CVA

72 (18)

121 (13.1)

76 (14.5)

.15

.47

Recent bleeding

16 (4)

54 (5.9)

27 (5.1)

.41

.57

Remote bleeding

14 (3.5)

42 (4.6)

34 (6.5)

.04

.11

167 (41.8)

389 (43.1)

139 (26.5)

<.001

<.001

40 (10)

77 (8.3)

19 (3.6)

<.001

.001

(A)

Comorbidities, n (%)

Medications, n (%)
Antiplatelets
Nonsteroidal anti-
inflammatory drugs

Recurrent adverse events before procedure, n (%)
Thrombosis/stroke

8 (2)

10 (1.1)

6 (1.1)

.29

.92

Bleeding

70 (17.5)

191 (20.7)

59 (11.2)

.007

<.001

0.65 ± 0.15

0.66 ± 0.14

–

–

–

CHA 2DS2-VASc

3.12 ± 1.95

3.71 ± 1.69

3.54 ± 1.78

.001

.07

Modified HAS-BLED

2.66 ± 1.43

3.01 ± 1.34

2.58 ± 1.28

.35

<.001

241 (60.3)

397 (43.0)

158 (30.1)

<.001

<.001

Risk scores (Mean ± SD)
TTR

Procedure bleed risk, n (%)
High/medium

146 (36.5)

499 (54.1)

364 (69.3)

<.001

<.001

AF as indication

Low

141 (35.3)

677 (73.4)

371 (70.7)

<.001

.27

Duration of
anticoagulation
before procedure,
median days (IQR)

391 (706)

480 (806)

243 (258)

<.001

<.001

Days from stop to
procedure median
(IQR)

5 (0)

5 (1)

3 (2)

<.001

<.001

Days from procedure to
restart median (IQR)

1 (0, 2)

0 (0, 1)

1 (0, 2)

.80

.002

Apixaban 2.5 mg twice
daily

-

–

9

–

–

Apixaban 5 mg twice
daily

–

–

29

–

–

Apixaban 10 mg twice
daily

–

–

1

–

–

Dabigatran 150 mg
twice daily

–

–

1

–

–

Edoxaban 60 mg every
day

–

–

1

–

–

DOAC dosage at bleed

(Continues)
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TA B L E 1 (Continued)
Warfarin (Bridged)
n = 400

Warfarin (Nonbridged)
n = 923

DOAC
n = 525

p-value Warfarin
Bridged vs. DOAC

p-value Warfarin
Nonbridged vs. DOAC

Rivaroxaban 15 mg
every day

–

–

2

–

–

Rivaroxaban 20 mg
every day

–

–

28

–

–

Apixaban 5 mg twice
daily

–

–

3

–

–

Edoxaban 60 mg twice
daily

–

–

1

–

–

(A)

DOAC dosage at clot

Warfarin (Bridged)
n = 400

Warfarin
(Nonbridged)
n = 923

Any minor bleeds

34 (8.5)

Major bleeds
TIA/stroke/VTE
CRNMBs

n (%)

DOAC n = 525

p-value Warfarin
Bridged vs. DOAC

p-value Warfarin
Nonbridged vs.
DOAC

43 (4.7)

57 (10.8)

.23

<.001

13 (3.3)

10 (1.1)

15 (2.9)

.73

.01

3 (0.8)

5 (0.5)

4 (0.8)

.98

.61

26 (6.5)

28 (3)

34 (6.5)

.99

.002

(B)

Abbreviations: AF, atrial fibrillation; CRNMB, clinically relevant nonmajor bleeding; CVA, cardiovascular accident; DOAC, direct oral anticoagulant;
HTN, hypertension; IQR, interquartile range; TIA, transient ischemic accident; TTR, time in therapeutic range.

F I G U R E 2 Inverse probability of treatment weighting outcomes
statistical power and generalizability. This approach was not taken

thus reduce the effect of confounding variables on outcomes, the

with most other studies comparing DOAC and warfarin outcomes

samples for these studies are limited to patients who are eligible for

in the perioperative period.7–10 Although each of those analyses

randomization. In contrast, our data were not limited to patients el-

were conducted on randomized, controlled trial populations and

igible for randomization, therefore representing a potentially more

|
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generalizable estimate of adverse event rates. Last, our analysis dis-

fees), Board of Directors for Anticoagulation Forum (other), Scientific

tinguishes between warfarin-treated patients into both a bridged

Advisory Board for National Blood Clot Alliance (other), PERT

and a nonbridged cohort, which is critical given the strong evidence

Consortium (other). J. Froehlich: Merck (personal fees), Janssen

associating use of bridging therapy with increased bleeding risk. 2–4

(personal fees), Novartis (personal fees), Boehringer-Ingelheim (per-

Despite these strengths, certain limitations must be acknowl-

sonal fees), Pfizer (personal fees), Blue Cross Blue Shield of Michigan

edged. First, the modest sample sizes and inclusion of patients from

(grant), Fibromuscular Disease Society of America (grant). G. Barnes:

one geographic region may limit generalizability. Second, data on

Pfizer/Bristol-Myers Squibb (personal fees), Janssen (personal

exact perioperative management of DOACs was not available for

fees), Acelis (personal fees), AMAG Pharmaceuticals (personal fees),

this analysis. Therefore, it is unclear whether our DOAC periopera-

Connected Health (personal fees), Blue Cross Blue Shield of Michigan

tive interruption practices are fully consistent with the PAUSE pro-

(grant), Board of Directors: Anticoagulation Forum (other), Board of

tocol. Third, as with any retrospective cohort study, our analysis is

Directors: National Certification Board of Anticoagulation Providers

only as accurate as what is depicted in our electronic health records

(other). The remaining authors have no conflicts of interest to report.

and cannot account for things such as misinformation or lapses in
data. Fourth, although the use of IPTW methodology significantly

ORCID

reduces the impact of confounding in the analysis, covariate bal-

Jeffrey Lee

ance between the two groups are notably different before and after

Xiaowen Kong

https://orcid.org/0000-0003-4548-3600

the probability weighting is applied. Fifth, data on the rationale for

Brian Haymart

https://orcid.org/0000-0001-8484-6393

https://orcid.org/0000-0001-6906-2638

2

Scott Kaatz

https://orcid.org/0000-0002-3080-3328

dataset. Sixth, we do not have data on the use of prophylactic-dose

Vinay Shah

https://orcid.org/0000-0001-8489-3675

heparin in the periprocedural period. Seventh, we are only able to

Mona A. Ali

https://orcid.org/0000-0003-2416-6702

comment on association, not causation. Last, although we used a

Jay Kozlowski

fairly comprehensive list of confounding variables for our matching

James Froehlich

procedure, it is possible that there are other confounding factors

Geoffrey D. Barnes

why bridging was or was not given were not available in the MAQI

https://orcid.org/0000-0002-7950-0096
https://orcid.org/0000-0003-2327-8235
https://orcid.org/0000-0002-6532-8440

that were not included and influenced our results.
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CO N C LU S I O N

Our study suggests that the periprocedural interruption of DOACs
may be associated with a higher incidence of 30-day minor bleeds,
major bleeds, and bleeds requiring medical therapy when compared
with the interruption of nonbridged warfarin. However, no difference in bleeding or thromboembolic events was noted between
patients with warfarin who received bridging therapy and DOAC-
treated patients. Further studies that investigate the effects of
perioperative interruption of DOACs and warfarin on postoperative
outcomes while addressing potential issues of confounding variables
are warranted.
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